Live-single-cell phenotypic cancer biomarkers-future role in precision oncology?

Abstract The promise of precision and personalized medicine is rooted in accurate, highly sensitive, and specific disease biomarkers. This is particularly true for cancer-a disease characterized by marked tumor heterogeneity and diverse molecular signatures. Although thousands of biomarkers have bee...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Grannum R. Sant, Kevin B. Knopf, David M. Albala
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2017
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/adb7c741220b4a5fbd1231712d4b9900
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:adb7c741220b4a5fbd1231712d4b9900
record_format	dspace
spelling	oai:doaj.org-article:adb7c741220b4a5fbd1231712d4b99002021-12-02T14:22:13ZLive-single-cell phenotypic cancer biomarkers-future role in precision oncology?10.1038/s41698-017-0025-y2397-768Xhttps://doaj.org/article/adb7c741220b4a5fbd1231712d4b99002017-06-01T00:00:00Zhttps://doi.org/10.1038/s41698-017-0025-yhttps://doaj.org/toc/2397-768XAbstract The promise of precision and personalized medicine is rooted in accurate, highly sensitive, and specific disease biomarkers. This is particularly true for cancer-a disease characterized by marked tumor heterogeneity and diverse molecular signatures. Although thousands of biomarkers have been described, only a very small number have been successfully translated into clinical use. Undoubtedly, there is need for rapid, quantitative, and more cost effective biomarkers for tumor diagnosis and prognosis, to allow for better risk stratification and aid clinicians in making personalized treatment decisions. This is particularly true for cancers where specific biomarkers are either not available (e.g., renal cell carcinoma) or where current biomarkers tend to classify individuals into broad risk categories unable to accurately assess individual tumor aggressiveness and adverse pathology potential (e.g., prostate cancer), thereby leading to problems of over-diagnosis and over-treatment of indolent cancer and under-treatment of aggressive cancer. This perspective highlights an emerging class of cancer biomarkers-live-single-cell phenotypic biomarkers, as compared to genomic biomarkers, and their potential application for cancer diagnosis, risk-stratification, and prognosis.Grannum R. SantKevin B. KnopfDavid M. AlbalaNature PortfolioarticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENnpj Precision Oncology, Vol 1, Iss 1, Pp 1-7 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Grannum R. Sant Kevin B. Knopf David M. Albala Live-single-cell phenotypic cancer biomarkers-future role in precision oncology?
description	Abstract The promise of precision and personalized medicine is rooted in accurate, highly sensitive, and specific disease biomarkers. This is particularly true for cancer-a disease characterized by marked tumor heterogeneity and diverse molecular signatures. Although thousands of biomarkers have been described, only a very small number have been successfully translated into clinical use. Undoubtedly, there is need for rapid, quantitative, and more cost effective biomarkers for tumor diagnosis and prognosis, to allow for better risk stratification and aid clinicians in making personalized treatment decisions. This is particularly true for cancers where specific biomarkers are either not available (e.g., renal cell carcinoma) or where current biomarkers tend to classify individuals into broad risk categories unable to accurately assess individual tumor aggressiveness and adverse pathology potential (e.g., prostate cancer), thereby leading to problems of over-diagnosis and over-treatment of indolent cancer and under-treatment of aggressive cancer. This perspective highlights an emerging class of cancer biomarkers-live-single-cell phenotypic biomarkers, as compared to genomic biomarkers, and their potential application for cancer diagnosis, risk-stratification, and prognosis.
format	article
author	Grannum R. Sant Kevin B. Knopf David M. Albala
author_facet	Grannum R. Sant Kevin B. Knopf David M. Albala
author_sort	Grannum R. Sant
title	Live-single-cell phenotypic cancer biomarkers-future role in precision oncology?
title_short	Live-single-cell phenotypic cancer biomarkers-future role in precision oncology?
title_full	Live-single-cell phenotypic cancer biomarkers-future role in precision oncology?
title_fullStr	Live-single-cell phenotypic cancer biomarkers-future role in precision oncology?
title_full_unstemmed	Live-single-cell phenotypic cancer biomarkers-future role in precision oncology?
title_sort	live-single-cell phenotypic cancer biomarkers-future role in precision oncology?
publisher	Nature Portfolio
publishDate	2017
url	https://doaj.org/article/adb7c741220b4a5fbd1231712d4b9900
work_keys_str_mv	AT grannumrsant livesinglecellphenotypiccancerbiomarkersfutureroleinprecisiononcology AT kevinbknopf livesinglecellphenotypiccancerbiomarkersfutureroleinprecisiononcology AT davidmalbala livesinglecellphenotypiccancerbiomarkersfutureroleinprecisiononcology
_version_	1718391509249687552

Live-single-cell phenotypic cancer biomarkers-future role in precision oncology?

Ejemplares similares